12:00 AM
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CPI-613: Additional Phase I data

Data from 7 evaluable patients who received >=1 cycle of treatment in an open-label, dose-escalation, U.S. Phase I trial showed that twice-weekly IV CPI-613 for 3 weeks led to complete remission in 1 patient and a morphologically...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >